These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38226620)

  • 1. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
    Okato A; Utsumi T; Ranieri M; Zheng X; Zhou M; Pereira LD; Chen T; Kita Y; Wu D; Hyun H; Lee H; Gdowski AS; Raupp JD; Clark-Garvey S; Manocha U; Chafitz A; Sherman F; Stephens J; Rose TL; Milowsky MI; Wobker SE; Serody JS; Damrauer JS; Wong KK; Kim WY
    J Clin Invest; 2024 Jan; 134(2):. PubMed ID: 38226620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Qin Q; Patel V; Galsky MD
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder Cancer by Abrogating Immunosuppression.
    St-Laurent MP; Black PC
    Eur Urol; 2024 Aug; 86(2):184-185. PubMed ID: 38614823
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
    Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
    BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 7. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
    BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
    Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
    Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
    Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
    Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
    Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
    Bergman DR; Wang Y; Trujillo E; Fernald AA; Li L; Pearson AT; Sweis RF; Jackson TL
    Front Immunol; 2024; 15():1358019. PubMed ID: 38515743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
    Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
    Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
    Benjamin DJ; Hsu R
    Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
    Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI
    Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
    di Martino E; Alder O; Hurst CD; Knowles MA
    Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
    Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
    Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P4HA2-mediated HIF-1α stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
    Li X; Li Y; Liu B; Chen L; Lyu F; Zhang P; He Q; Cheng L; Liu C; Song Y; Xing Y
    FASEB J; 2023 Apr; 37(4):e22840. PubMed ID: 36943397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
    Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
    Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
    Zengin ZB; Chehrazi-Raffle A; Salgia NJ; Muddasani R; Ali S; Meza L; Pal SK
    Urol Oncol; 2022 Feb; 40(2):25-36. PubMed ID: 34840077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
    Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
    Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.